Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis

Leukemia. 2020 Nov;34(11):3082-3084. doi: 10.1038/s41375-020-0905-y. Epub 2020 Jun 9.

Authors

Kelly J Norsworthy¹, Armen Avagyan², Steven T Bird³, Yuchen Li², Sandia Akhtar², Jiemin Liao², Michael Wernecke², Albert B Deisseroth³, Meredith Chuk⁴, Thomas E MaCurdy^{2

5}, Richard Swain³, Jeffrey A Kelman⁶, Ann T Farrell³, R Angelo de Claro³, Richard Pazdur⁴, Gideon Blumenthal⁴, David J Graham³

Affiliations

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. kelly.norsworthy@fda.hhs.gov.
² Acumen LLC, Burlingame, CA, USA.
³ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
⁴ Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA.
⁵ Department of Economics, Stanford University, Stanford, CA, USA.
⁶ Centers for Medicare & Medicaid Services, Washington, DC, USA.

PMID: 32518418
DOI: 10.1038/s41375-020-0905-y

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Arsenic Trioxide / administration & dosage
Arsenic Trioxide / adverse effects*
Female
Humans
Incidence
Leukemia, Promyelocytic, Acute / drug therapy
Leukemia, Promyelocytic, Acute / epidemiology*
Leukemia, Promyelocytic, Acute / mortality
Male
Medicare
Neoplasms, Second Primary / epidemiology*
Neoplasms, Second Primary / etiology*
Prognosis
SEER Program
United States / epidemiology

Substances

Arsenic Trioxide

Grants and funding